Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)

NCT ID: NCT03942120

Last Updated: 2025-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

685 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-08

Study Completion Date

2022-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of post-marketing surveillance (PMS) is to assess the safety and effectiveness of ustekinumab (Stelara) for Crohn's disease participants under real world clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Crohn's Disease

Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.

Ustekinumab

Intervention Type DRUG

Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ustekinumab

Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stelara

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who are administered with Stelara for the first time for the indication of Crohn's disease in accordance with the label
* Participants must sign a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements

Exclusion Criteria

\- Have contraindication to Stelara in accordance to the label
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Korea, Ltd., Korea

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Korea, Ltd., Korea Clinical Trial

Role: STUDY_DIRECTOR

Janssen Korea, Ltd., Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Inje University Busan Paik Hospital

Busan, , South Korea

Site Status

Inje University Haeundae Paik Hospital

Busan, , South Korea

Site Status

Kosin University Gospel Hospital

Busan, , South Korea

Site Status

Good Gangan Hospital

Busan, , South Korea

Site Status

Pusan National University Hospital

Busan, , South Korea

Site Status

Dong-A University Hospital

Busan, , South Korea

Site Status

Samsung ChangWon Hospital

Changwon, , South Korea

Site Status

Changwon Kyunngsang University Hospital

Changwonsi, , South Korea

Site Status

Soonchunhyang University Cheonan Hospital

Cheonan, , South Korea

Site Status

Dankook University Hospital

Cheonan-si, , South Korea

Site Status

Hallym University Chuncehon Medical Center

Chuncheon, , South Korea

Site Status

Kangwon National University Hospital

Chuncheon, , South Korea

Site Status

Daegu Fatima Hospital

Daegu, , South Korea

Site Status

Kyongpook national university Medical center

Daegu, , South Korea

Site Status

Kyungpook National University Chilgok Hospital

Daegu, , South Korea

Site Status

Kyungpook National University Hospital

Daegu, , South Korea

Site Status

Yeungnam University Medical Center

Daegu, , South Korea

Site Status

Keimyung University Dongsan Hospital

Daegu, , South Korea

Site Status

Koo Hospital

Daegu, , South Korea

Site Status

Konyang University Hospital

Daejeon, , South Korea

Site Status

Chungnam National University Hospital

Daejeon, , South Korea

Site Status

Chunnam National University Hospital

Gwangju, , South Korea

Site Status

Seoul National University Bundang Hospital

Gyeonggi-do, , South Korea

Site Status

Korea University Ansan Hospital

Gyeonggi-do, , South Korea

Site Status

Hallym University Dongtan Sacred Heart Hospital

Hwaseong-si, , South Korea

Site Status

GyeongSang National University Hospital

Jinju, , South Korea

Site Status

Bucheon Soonchunhyang Hospital

Kyunggido, , South Korea

Site Status

The Catholic Univ. of Korea, DaeJeon St. Mary's Hospital

Seongnam, , South Korea

Site Status

CHA Bundang Medical Center, CHA University

Seongnam, , South Korea

Site Status

Pusan National University Yangsan Hospital

Seoul, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Kangbuk Samsung Hospital

Seoul, , South Korea

Site Status

Soonchunhyang University Seoul Hospital

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Hallym University Medical Center

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

The Catholic University of Korea Seoul St Mary s Hospital

Seoul, , South Korea

Site Status

Chung-Ang University Hospital

Seoul, , South Korea

Site Status

KyungHee University Hospital

Seoul, , South Korea

Site Status

Yonsei University Severance Hospital - Dept.of Internal Medicine

Seoul, , South Korea

Site Status

Gangnam Severance Hospital

Seoul, , South Korea

Site Status

Ewha Woman's University Seoul Hospital

Seoul, , South Korea

Site Status

Pusan National University Yangsan Hospital

Yangsan, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Lee CK, Moon W, Chun J, Kim ES, Kim HW, Yoon H, Kim HS, Lee YJ, Choi CH, Jung Y, Park SC, Song GA, Lee JH, Jung ES, Kim Y, Jung SY, Choi JM, Ye BD. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study. Inflamm Bowel Dis. 2025 May 12;31(5):1306-1316. doi: 10.1093/ibd/izae171.

Reference Type DERIVED
PMID: 39096895 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CNTO1275CRD4029

Identifier Type: OTHER

Identifier Source: secondary_id

CR108610

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.